Table 3 Genotypes of the SNPs and the association with presence/absence of antibodies
Antibody type | SNP | Genotype | With antibody, N (%) | Without antibody, N (%) | Model | Comparison | OR (95% CI) | p-value |
|---|---|---|---|---|---|---|---|---|
MSP1-19_Pv | rs739718 (IL5) | TT | 165 (70.2) | 70 (29.8) | Co-dominant | TT/CT | 5.893 (1.117–31.101) | 0.019 |
| Â | CT | 2 (28.6) | 5 (71.4) | Â | Â | Â | Â | |
MSP1-19_Pf | rs6874639 (C5ORF56) | AA | 37 (39.4) | 57 (60.6) | Co-dominant | AG/AA | 2.054 (1.116–3.618) | 0.12 |
|  | AG | 60 (57.1) | 45 (42.9) | Co-dominant | GG/AG | 2.872 (1.339–6.159) | 0.006 | |
|  | GG | 13 (31.7) | 28 (68.3) | Dominant | AG/AA + GG | 2.267 (1.364–3.816) | 0.002 | |
|  |  |  |  | Dominant | GG/AA +AG | 0.488 (0.239–0.997) | 0.046 | |
rs2706379 (C5ORF56) | CC | 38 (38.4) | 61 (61.6) | Co-dominant | CT/CC | 2.203 (1.253–3.873) | 0.006 | |
|  | CT | 59 (57.8) | 43 (42.2) | Co-dominant | CT/TT | 2.639 (1.213–5.738) | 0.013 | |
|  | TT | 13 (34.2) | 25 (65.8) | Dominant | CC/CT + TT | 0.588 (0.349–0.993) | 0.046 | |
|  |  |  |  | Dominant | CT/CC + TT | 2.314 (1.370–3.907) | 0.002 | |
|  | rs2706381 (C5ORF56) | CC | 38 (38.4) | 61 (61.6) | Co-dominant | CT/CC | 2.165 (1.230–3.811) | 0.007 |
|  | CT | 58 (57.4) | 43 (42.6) | Co-dominant | CT/TT | 2.698 (1.244–5.849) | 0.011 | |
|  | TT | 13 (33.3) | 26 (66.7) | Dominant | CT/CC + TT | 2.301 (1.362–3.888) | 0.002 | |
rs2075820 (NOD1) | AA | 29 (64.4) | 16 (35.6) | Co-dominant | AA/AG | 2.595 (1.261–5.341) | 0.009 | |
|  |  | AG | 44 (41.1) | 63 (58.9) | Co-dominant | AA/GG | 2.665 (1.259–5.642) | 0.009 |
|  |  | GG | 34 (40.5) | 50 (59.5) | Dominant | AA/AG + GG | 2.626 (1.337–5.158) | 0.004 |
AMA1_Pv | rs2075820 (NOD1) | AA | 42 (93.3) | 3 (6.7) | Co-dominant | AA/AG | 4.725 (1.354–16.49) | 0.009 |
|  | AG | 80 (74.8) | 27 (25.2) | Co-dominant | AA/GG | 5.60 (1.583–19.80) | 0.004 | |
|  | GG | 60 (71.4) | 24 (28.6) | Dominant | AA/AG + GG | 5.10 (1.514–17.17) | 0.004 |